Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$312.47 USD

312.47
1,973,664

-2.25 (-0.71%)

Updated May 17, 2024 04:00 PM ET

After-Market: $312.53 +0.06 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Amgen (AMGN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $196.94, marking a +0.66% move from the previous day.

Sejuti Banerjea headshot

5 Safe Bets for a Rocky Market

by Sejuti Banerjea

Here are 5 companies with proven track records.

Amgen, Walt Disney, Microsoft, Apple and Oracle highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Amgen, Walt Disney, Microsoft, Apple and Oracle highlighted as Zacks Bull and Bear of the Day

Ekta Bagri headshot

3 Big Biotech Stocks Worth Adding to Your Portfolio Now

by Ekta Bagri

We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.

David Borun headshot

Bull of the Day: Amgen (AMGN)

by David Borun

One of the world's original biotech companies is still on top of the heap after almost 40 years.

Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

by Zacks Equity Research

Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma

by Zacks Equity Research

Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.

Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

by Zacks Equity Research

The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold

Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

by Zacks Equity Research

Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of September 16, 2019

by Panel Of Zacks Experts

A Biotech Pioneer and an E-Commerce Giant.

Aimmune's Peanut Allergy Drug Gets FDA Committee's Support

by Zacks Equity Research

Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.

John Blank headshot

Why Cut the Fed Funds Rate Again? Global Week Ahead

by John Blank

It could be to keep policy and risk-free benchmark Treasury rates in alignment with the ECB's easing last week. It could be to alleviate trade war uncertainty. It could be to assist in next year???s U.S. Presidential election.

Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study

by Zacks Equity Research

Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.

Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

by Zacks Equity Research

Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.

Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study

by Zacks Equity Research

Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.

The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson

REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%

by Zacks Equity Research

REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.

Mark Vickery headshot

Top Research Reports for Amgen, Cisco & Berkshire Hathaway

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and Berkshire Hathaway (BRK.B).

Ultragenyx to Submit sBLA for Label Expansion of Crysvita

by Zacks Equity Research

Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.

Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.

Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

by Zacks Equity Research

Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.

Company News For Sep 10, 2019

by Zacks Equity Research

Companies In The News Are: T,AA,AMGN,BA